Early Warning System for Allergic Rhinitis in the MASK-air® App
ConditionAllergic Rhinitis
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversidade do Porto
About this trial
The primary objective consists in the comparison of the combined symptom medication score values between (i) patients randomised to the early warning system personalised forecasting messages, and (ii) patients randomised to generic messages already delivered by MASK-air®.
The combined symptom medication score has recently been developed in a data-driven way and validated (https://eaaci.org/images/CSMS.pdf); it assesses allergic rhinitis control taking into account both reported symptoms and medication use.
As secondary objectives, visual analogue scales on allergic rhinitis symptoms (VAS global, nasal, eye, asthma), and medication use will also be separately compared.
Eligibility criteria
Qualifiers
None
Disqualifiers
Illiterate patients
Patients without smartphone
Patients who are not able to complete a daily monitoring questionnaire on allergic rhinitis.
Trial design
Treatments tested in this trial
- Personalised early warning system
Treatment groups
210 Participants
are divided into 2 treatment groupsSponsors and collaborators
Universidade do Porto
Lead sponsor
Centro Hospitalar De São João, E.P.E.
Collaborator
Source ClinicalTrials.gov